Deals channel feed

Lil­ly makes an­oth­er move for Verve's ge­net­ic med­i­cines, this time buy­ing Beam's opt-in rights

Last year
Pharma
Cell/Gene Tx

Mer­ck KGaA pays $169M up­front in deal for Hen­grui’s PARP1 in­hibitor and ADC

Last year
R&D

Deal flow in­flux: Abing­worth's new $356M fund will help Big Phar­ma ex­pand drug la­bels

Last year
Financing
Pharma

Ac­cen­ture boosts life sci­ences mar­ket­ing in $245M deal for No­vo Nordisk's obe­si­ty ad agency Con­cen­tri­cLife

Last year
Pharma
Marketing

How Bris­tol My­er­s' buy­out of­fer for Mi­rati dwin­dled by bil­lions of dol­lars

Last year

Bris­tol My­ers pays $350M up­front for rights to heart drug Camzyos in Asia

Last year

Roivant CEO urges pa­tience on fu­ture af­ter $7B+ sale to Roche

Last year
Pharma

You get an ADC, you get an ADC: Phar­mas bite on on­col­o­gy’s buzzi­est class

Last year
R&D
In Focus

Mer­ck ax­es two of nine AD­Cs in pact with Kelun-Biotech

Last year
China
Pharma

Roivant flips ul­cer­a­tive col­i­tis drug to Roche for $7.1B, less than a year af­ter get­ting the drug from Pfiz­er

Last year
Pharma

Every­one wants an ADC: GSK pays $85M up­front for ex-Chi­na rights to Han­soh Phar­ma's an­ti­body-drug con­ju­gate

Last year

#ES­MO23 dis­patch: What to know about the HER3 ADC that got Mer­ck to pay $2B cash

Last year

Mer­ck dou­bles down on AD­Cs with $4B up­front to Dai­ichi Sankyo, go­ing for ‘same in­ten­si­ty’ as megablock­buster Keytru­da

Last year

PTC to sell roy­al­ties on block­buster SMA drug Evrys­di for up to $1.5B

Last year
Pharma

Syn­cona eyes buy­out of gene ther­a­py biotech Free­line af­ter ear­ly da­ta in two Gauch­er pa­tients

Last year
Cell/Gene Tx

Scoop: Eli Lil­ly agrees to ac­quire an­oth­er Eu­ro­pean ADC biotech

Last year
Startups
Pharma

Q&A: Lil­ly sci­ence chief Dan Skovron­sky talks deal­mak­ing, AI and con­sis­tent in­vest­ing

Last year
Pharma

Ther­mo Fish­er reels in pro­teomics com­pa­ny Olink in $3.1B deal

Last year
Outsourcing

Roche en­lists Monte Rosa for can­cer, neu­ro dis­cov­ery deal with $50M up­front

Last year

PureTech gives up on re­gain­ing con­trol of Gele­sis and its weight loss pill

Last year

Gilead makes a $100M bet that As­sem­bly Bio can ad­vance an­tivi­rals, toss­ing life­line to strug­gling biotech

Last year

Spark lines up next reti­nal gene ther­a­py pact in Barcelona

Last year
Pharma
Cell/Gene Tx

Lon­za un­veils two sep­a­rate vac­cine, ADC man­u­fac­tur­ing deals that could lead to 415 new Swiss jobs

Last year
Manufacturing

No­vo Nordisk to buy PhI­II kid­ney dis­ease drug from Sin­ga­pore's KBP Bio­sciences

Last year
Pharma
First page Previous page 26272829303132 Next page Last page
A service from the Financial Times